Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells

Código QR

Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells

Abstract It is not clear how Fms-like tyrosine kinase 3-internal tandem duplications (FLT3-ITD) regulates checkpoint kinase 1 (CHK1) in acute myeloid leukemia (AML). In this study, we investigated the regulatory effect of FLT3-ITD on CHK1. Our results showed that CHK1 was highly expressed in FLT3-IT...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yudong Zhang, Lingli Yuan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4a50f3ef8289495fbac690663ca81f9e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
por: Petrushev B, et al.
Publicado: (2016)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Yundeok Kim, et al.
Publicado: (2021)

Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis.
por: Sofia E M Andersson, et al.
Publicado: (2012)

Molecular Modeling Studies of <i>N</i>-phenylpyrimidine-4-amine Derivatives for Inhibiting FMS-like Tyrosine Kinase-3
por: Suparna Ghosh, et al.
Publicado: (2021)

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors
por: Hyeok-Jae Jang, et al.
Publicado: (2021)

Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
por: Mohamed A. Ismail, et al.
Publicado: (2021)

Pseudogene fms-related tyrosine kinase 1 pseudogene 1 (FLT1P1) cooperates with RNA binding protein dyskeratosis congenita 1 (DKC1) to restrain trophoblast cell proliferation and angiogenesis by targeting fms-related tyrosine kinase 1 (FLT1) in preeclampsia
por: Zhenjing Chi, et al.
Publicado: (2021)

Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
por: Tan BK, et al.
Publicado: (2021)

THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
por: Mohammad Abu-Tineh, et al.
Publicado: (2021)

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
por: Natalie J. Hannan, et al.
Publicado: (2017)

Use of tyrosine kinase inhibitor by patients with chronic myeloid leukemia at a public hematology institution in the state of Amazonas, Brazil
por: Andreia D. MENEZES, et al.
Publicado: (2020)

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
por: Rory M. Shallis, et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: C. I. Edvard Smith, et al.
Publicado: (2021)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Sachin Gupta, et al.
Publicado: (2008)

Circular RNAs in acute myeloid leukemia
por: Vijendra Singh, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
por: Leigh Naylor-Adamson, et al.
Publicado: (2021)

Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
por: Nicholas M Levinson, et al.
Publicado: (2012)

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.
por: Young H Lee, et al.
Publicado: (2021)

Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer
por: Nan Jin, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

Neurotrophin receptor tyrosine kinases regulated with near-infrared light
por: Anna V. Leopold, et al.
Publicado: (2019)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto RA, et al.
Publicado: (2015)

Peptidomimetic blockade of MYB in acute myeloid leukemia
por: Kavitha Ramaswamy, et al.
Publicado: (2018)

NEW ADVANCES IN PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Özlem Tüfekçi
Publicado: (2021)

In-Silico Drug discovery approach targeting receptor tyrosine kinase-like orphan receptor 1 for cancer treatment
por: Onkar Nath, et al.
Publicado: (2017)

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4
por: Konstantinos Tzelepis, et al.
Publicado: (2018)

Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis.
por: Wanhua Zhang, et al.
Publicado: (2021)

Is stem cell transplantation still needed for adult Philadelphia chromosome-positive acute lymphoblastic leukemia receiving tyrosine kinase inhibitors therapy?: A systematic review and meta-analysis.
por: Ben Ponvilawan, et al.
Publicado: (2021)

Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
por: Thomas X
Publicado: (2012)

The protein kinase CK2 catalytic domain from Plasmodium falciparum: crystal structure, tyrosine kinase activity and inhibition
por: David Ruiz-Carrillo, et al.
Publicado: (2018)

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
por: Agnieszka Kaczmarska, et al.
Publicado: (2021)

Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
por: Rafael Roesler, et al.
Publicado: (2021)

Diverse Requirements for Src-Family Tyrosine Kinases Distinguish Chlamydial Species
por: Jeffrey Mital, et al.
Publicado: (2011)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sareshma Sudhesh Dev, et al.
Publicado: (2021)

Reprogramming signal transduction through a designer receptor tyrosine kinase
por: Tatphon Kongkrongtong, et al.
Publicado: (2021)

Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures
por: Giulia Franciosa, et al.
Publicado: (2021)

A rare gain of function mutation in a wheat tandem kinase confers resistance to powdery mildew
por: Ping Lu, et al.
Publicado: (2020)

The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
por: Débora Bifano Pimenta, et al.
Publicado: (2021)

EXPERIENCE OF GLASDEGIB IN PATIENTS WITH ELDERLY ACUTE MYELOID LEUKEMIA
por: Nanişe Gizem FENER, et al.
Publicado: (2021)

Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis
por: Fabian Schuler, et al.
Publicado: (2017)